MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead asset, ateganosine (THIO, 6-thio-dG), is an investigational dual mechanism drug candidate targeting telomeres and inducing immunogenicity. Ateganosine is being evaluated primarily in Non-Small Cell Lung Cancer (NSCLC) in Phase 2 (THIO-101) and Phase 3 (THIO-104) trials, with planned Phase 2 trials in hepatocellular carcinoma, colorectal cancer, and small cell lung cancer.
Q2 FY2026 — expected 2026-09-26
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001493152-26-012088 | EDGAR | 113K words |
| 2025-03-21 | 2024-12-31 | 0000950170-25-043190 | EDGAR | 97K words |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034764 | EDGAR | 90K words |
| 2023-03-24 | 2022-12-31 | 0000950170-23-009766 | EDGAR | 91K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001493152-26-036764 | EDGAR | 24K words |
| 2025-11-07 | 2025-09-30 | 0001493152-25-021272 | EDGAR | 32K words |
| 2025-08-11 | 2025-06-30 | 0001641172-25-022899 | EDGAR | 26K words |
| 2025-05-09 | 2025-03-31 | 0000950170-25-068005 | EDGAR | 21K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125474 | EDGAR | 25K words |
| 2024-08-09 | 2024-06-30 | 0000950170-24-094747 | EDGAR | 23K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059550 | EDGAR | 21K words |
| 2023-11-07 | 2023-09-30 | 0000950170-23-059778 | EDGAR | 21K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039399 | EDGAR | 19K words |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018480 | EDGAR | 17K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023956 | EDGAR | — |
| 2022-08-22 | 2022-06-30 | 0000950170-22-017637 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001493152-26-014924 | EDGAR | 1K words |
| 2026-03-31 | 0001493152-26-013879 | EDGAR | 1K words |
| 2026-03-27 | 0001493152-26-013088 | EDGAR | 1K words |
| 2026-03-04 | 0001493152-26-008897 | EDGAR | 1K words |
| 2026-02-24 | 0001493152-26-007831 | EDGAR | 1K words |
| 2026-01-20 | 0001493152-26-002883 | EDGAR | 1K words |
| 2026-01-13 | 0001493152-26-002085 | EDGAR | 0K words |
| 2025-12-17 | 0001493152-25-028041 | EDGAR | 1K words |
| 2025-12-11 | 0001493152-25-027244 | EDGAR | 1K words |
| 2025-12-10 | 0001493152-25-027072 | EDGAR | 1K words |
148 total filings indexed. 122 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001878313 |
| Ticker | MAIA |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | Chicago, Illinois |
| Website | https://www.maiabiotech.com |
| Listed | 2022-07-28 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/MAIA (~200 tokens, structured JSON with cryptographic provenance)